美罗华联合化疗治疗B细胞非霍奇金淋巴瘤  

Clinical observation of rituximab in combination with CHOP chemotherapy for B cell non-Hodgkin lymphoma

作　　者：严怀秀[1] 王丹彤[1] 

机构地区：[1]内蒙古医学院第三附属医院血液科,内蒙古包头014010

出　　处：《中国冶金工业医学杂志》2008年第6期654-655,共2页Chinese Medical Journal of Metallurgical industry

摘　　要：目的:观察美罗华联合CHOP方案治疗B细胞非霍奇金淋巴瘤的疗效及不良反应。方法:9例B细胞非霍奇淋巴瘤患者采用4～6个周期的美罗华加CHOP方案治疗,每1周期21天,于每1周期的第1天予美罗华(375mg/m2)静脉滴注,第3天开始予CHOP方案化疗。结果:9例患者中,完全缓解7例、部分缓解2例,总有效率为100;不良反应均可耐受,均出现Ⅰ～Ⅱ度骨髓抑制。结论:美罗华联合CHOP方案治疗B细胞非霍奇淋巴瘤疗效好,不良反应可以耐受。Objective：To evaluate the efficacy and toxicity of rituximab plus CHOP regimen in patients with B cell non--Hodgkin＇s lymphoma. Methods： 9 patients received 4 - 6 cycles of rituximab-CHOP combination therapy. There are twenty-one days in each cycle,of each cycle, a dose of rituximab（375 mg/m^2）was infused in the frjst day 1, CHOP regimen were administered in the third day. Results： There were 9 patients in the study. The complete remission was observed in 7 patients,and partial remission was observed in 2 patients. The total response rate was 100%. The therapy could be well to lerated Grade ⅠⅡ myelosup pression were observed in all the patients. Conclusions： Rituximab combined with chemotherapy is a highly effective and well-tolerated treatment in B cell non-Hodgkin＇s lymphoma.

关 键 词：B细胞 淋巴瘤 美罗华联合化疗治疗法 B细胞非霍奇金淋巴瘤 

分 类 号：R733.1[医药卫生—肿瘤]